6th Obesity and NASH Drug Development Summit 2022

Contact Name:
Jessica Durston
Phone:
+1 617 455 4188
E-mail:
info@hansonwade.com
Filed in:
Things to do near Boston, MA » Conferences » Science

The first wave of investment in NASH is dispersing in the wake of highly demanding biopsy endpoints, but opportunities to target obesity and metabolic syndrome are catalyzing increasing excitement. Pivotal readouts in GLP-1 receptor agonists and exciting progress in regenerative medicine and microRNAs are redefining the drug development landscape for metabolic disorders.

With mounting competition for the market in obesity and all eyes on the next wave of NASH candidates, the 6th Obesity and NASH Drug Development Summit, (previously the NASH Summit) is dedicated to reuniting industry leaders in metabolic syndrome to consolidate targets directly implicated in disease pathology and traverse the regulatory hurdles to commercialization.

Join 150+ industry pioneers in Boston including pioneers Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Pfizer, Inventiva, Regeneron, FDA, AstraZeneca, and more to advance your pipeline towards approved treatment.

URLs:
Website: https://go.evvnt.com/1277295-0?pid=176 
Tickets: https://go.evvnt.com/1277295-2?pid=176 
Brochure: https://go.evvnt.com/1277295-3?pid=176 

Time: 09:55 - 16:40

Prices:
Conference + Pre-Conference Day - Drug Developer: USD 4297.00,
Conference Only - Drug Developer: USD 2999.00,
Conference + Pre-Conference Day - Academic: USD 3697.00,
Conference Only - Academic: USD 2599.00,
Conference + Pre-Conference Day - Service Provider: USD 5097.00,
Conference Only - Service Provider: USD 3599.00

Speakers: Allison Goldfine, Director, Translational Medicine Cardiometabolic Disease, Novartis, Andrew Billin, Senior Director Biomarker Sciences, Gilead, Anjali Pandey, Senior Vice President Nonclinical R and D and Chemistry, Aria Pharmaceuticals, Arvid Söderhäll, Chief Executive Officer, Empros Pharma, Ashish Nimgaonkar, Founder and Chief Executive Officer, Glyscend, Clare Buckeridge, Clinical Lead Internal Medicine Research Unit, Pfizer, Cynthia Arbeeny, Chief Scientific Officer, Mitotherapeutix, George Kemble, Chief Executive Officer, Sagimet Biosciences, Ginnie (Hsiu-Chiung) Yang, Vice President, Therapeutic Area 2, Inflammation, Exploratory Pathobiology, Tissue Repair, Bayer, Helen Heymann, Senior Scientific Project Manager, Metabolic Disorders, Foundation for the National Institutes of Health, Henry Hsu, Chief Executive Officer, Allysta Pharmaceuticals, Jacob Jeppesen, Vice President Type 2 Diabetes and Cardiovascular Disease Research, Novo Nordisk, Jim Perfield, Executive Director Discovery Biology, Diabetes, Obesity and Complications, Eli Lilly and Company, Kitty Yale, Chief Development Officer, Akero Therapeutics, Leigh MacConell, Chief Development Officer, HighTide Therapeutics, Marc Thibonnier, Founder and President, AptamiR Therapeutics, Margaret Koziel, Chief Medical Officer, Axcella Therapeutics, Mathijs Bunck, Associate Vice President Medical Product Development, Tirzepatide Obesity, Eli Lilly and Company, Michael Cooreman, Chief Medical Officer, Inventiva Pharma, Michelle Long, International Medical Vice President, NASH, Novo Nordisk, Minjun Chen, Staff Fellow Division of Bioinformatics and Biostatistics, FDA, Morten Karsdal, Chief Executive Officer, Nordic Bioscience, Nezam Afdhal, Chief of the Division of Gastroenterology Hepatology and Nutrition, Beth Israel Deaconess Medical Center, Pascaline Clerc, Vice President of Global External Affairs, Inventiva Pharma, Paulo Fontes, Co-Founder and Chief Medical Officer, LyGenesis, Phil Ambery, Global Clinical Head, CVRM, AstraZeneca, Quin Wills, Co-Founder and Chief Scientific Officer, Ochre Bio, Pol Boudes, Chief Medical Officer, Galectin Therapeutics, Ramy Younes, Senior Clinical Program Leader NASH and Obesity, Boehringer Ingelheim, Ranabir SinhaRoy, Vice President and Global Program Head General Medicine, Regeneron, Rebecca Taub, Founder and Chief Medical Officer, Madrigal Pharmaceuticals, Richard Torstenson, Senior Director Global Regulatory Affairs, AstraZeneca, Salah Kivlighn, Chief Executive Officer, HepaTx, Sarah Sherlock, Senior Director, Clinical and Translational Imaging and Head of External Imaging Alliances, Pfizer, Scott Harris, Chief Medical Officer, Altimmune, Scott Kelly, Chief Medical Officer, CytoDyn, Stan Watowich, Founder and Chief Executive Officer, Ridgeline Therapeutics, Stephanie VennWatson, Co-Founder and Chief Executive Officer, Epitracker, Sudha Shankar, Global Clinical Head NASH, AstraZeneca

http://www.eventsnearhere.com/find-events/MA/BOSTON/Conferences/Science/addetail/198579/6th-Obesity-and-NASH-Drug-Development-Summit-2022

Street Address

Revere Hotel Boston Common, 200 Stuart Street
Boston, MA 02116

Dates

through
  View Calendar